LPA and coronary artery disorder: These findings suggest that in established coronary artery disease, Lp(a) drives ASCVD-risk by promoting progression of vulnerable plaque phenotypes, providing a potential mechanistic explanation for the association between Lp(a) and clinical atherothrombotic events.